Spots Global Cancer Trial Database for STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Official Title: A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies
Study ID: NCT00858572
Interventions
Study Description
Brief Summary: The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Boston, Massachusetts, United States
, New York, New York, United States
, San Antonio, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
